## Probenecid - Furosemide DDI

**Britz 2020** Britz H, Hanke N, Taub ME, Wang T, Prasad B, Fernandez É, Stopfer P, Nock V, Lehr T. Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions. Pharm Res. 2020 Nov 25;37(12):250. doi: 10.1007/s11095-020-02964-z. 

**Shen 2019** Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, Marathe P, Humphreys WG. Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. J Pharmacol Exp Ther. 2019 Jan;368(1):136-145. doi: 10.1124/jpet.118.252643.  

**Smith 1980** Smith DE, Gee WL, Brater DC, Lin ET, Benet LZ. Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci. 1980 May;69(5):571-5. doi: 10.1002/jps.2600690526.

**Vree 1995** Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol. 1995 Jun;39(6):692-5.

**Wiebe 2020** Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, Ishiguro N, Taub ME, Sharma A, Ebner T, Mikus G, Fromm MF, Müller F, Stopfer P. Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clin Pharmacokinet. 2020 Dec;59(12):1627-1639. doi: 10.1007/s40262-020-00907-w.  



